SCHEMBL6603063

SCHEMBL6603063

COc1ccc(-c2coc(=O)[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.54
KDM4E B2RXH2 9/20 0.51
MAPT P10636 3/20 0.51
THRB P10828 1/20 0.51
PKM P14618 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 7/20 0.50
HPGD P15428 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
GAA P10253 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
NOTUM Q6P988 1/20 0.47
LMNA P02545 1/20 0.46
EGFR P00533 1/20 0.44
SCN4A P35499 1/20 0.44
BACE1 P56817 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27987820 0.83 ALDH1A1 (0.54) MAP2K1KDM4EMAPTTDP1ALDH1A1
SCHEMBL38658162 0.77 MEN1 (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL29144919 0.77 ERCC1 (0.46) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL6604025 0.77 ALDH1A1 (0.47) KDM4EMAPTTHRBALDH1A1HPGD
SCHEMBL12309805 0.76 NOTUM (0.46) KDM4EMAPTTDP1ALDH1A1SMN1; SMN2
SCHEMBL38657735 0.76 BRD4 (0.46) KDM4EMAPTTDP1ALDH1A1HPGD
SCHEMBL6310414 0.73 MAP2K1 (0.62) MAP2K1KDM4EMAPTTHRBPKM
SCHEMBL7271565 0.73 GCGR (0.41) MAPTLMNA
SCHEMBL16664761 0.73 NOTUM (0.46) NOTUMMEN1KMT2A
SCHEMBL1361621 0.73 NOTUM (0.46) RAB9ANOTUMBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 US disclosed
CN-117466833-A Chiral 2-oxazolidinone and asymmetric synthesis method thereof 三峡大学 2024-01-30 CN disclosed
EP-3059235-B1 TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS SUMITOMO CHEMICAL CO (JP) 2020-10-28 EP disclosed
EP-3059235-B1 TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS SUMITOMO CHEMICAL CO (JP) 2020-10-28 EP disclosed
US-10085450-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-10-02 US disclosed
US-20160270399-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-09-22 US disclosed
US-20160270399-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-09-22 US disclosed
EP-3059235-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME Sumitomo Chemical Company, Ltd. (JP) 2016-08-24 EP disclosed
EP-3059235-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME Sumitomo Chemical Company, Ltd. (JP) 2016-08-24 EP disclosed
WO-2015056806-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME 住友化学株式会社 2015-04-23 WO disclosed
US-6699995-B1 ALKYLATION AT 5-POSITION OF OXAZOLE BY REACTION WITH UNSATURATED COMPOUND IN PRESENCE OF ACID OR BASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
EP-1219610-B1 PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-02-25 EP disclosed
EP-1219610-A1 PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10085450-B2 Tetrazolinone compound and use thereof ROS1, TCOF1, RPS20 MAP2K1 3766/4885KDM4E 1468/4885MAPT 3692/4885
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MAP2K1 3124/4885KDM4E 1437/4885MAPT 2999/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MAP2K1 3124/4885KDM4E 1437/4885MAPT 2999/4885
US-20160270399-A1 TETRAZOLINONE COMPOUND AND USE THEREOF ROS1, TCOF1, RPS20 MAP2K1 3766/4885KDM4E 1468/4885MAPT 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.